Arteritis de células gigantes
Resumen
La Arteritis de Células Gigantes (ACG) es considerada uno de los síndromes vasculíticos más prevalentes. Afecta predominantemente a las arterias de mediano y gran calibre siendo la complicación más temida, una neuropatía óptica isquémica anterior que puede evolucionar a una pérdida irreversible de la visión. Los síntomas son causados por isquemia local debido al daño endovascular acompañado además de daño sistémico mediado por citoquinas. En los últimos años la ecografía doppler, la resonancia magnética y el PET scan fueron tomando importancia en la búsqueda de herramientas que puedan confirmar o excluir el diagnóstico de ACG sin embargo la biopsia de la arteria temporal (BAT) continúa siendo la prueba estándar para el diagnóstico de esta enfermedad.
Descargas
Citas
(1) González-Gay M, Vazquez-Rodriguez T, López-Diaz, Miranda-Filloy J, Gonzalez-Juanatey C, Epidemiology of GiantCell Arteritis and Polymyalgia Rheumatica. Arthritis & Rheumatism (ArthritisCare&Research). 2009;61(10):1454–1461.
(2) Kesten F, Aschwanden M, Gubser P, Glatz K , Daikeler T. Giant cell arteriitis – a changing entity Swiss Med Wkly. 2011;141:w13272 (art. on line).
(3) Salvarani C, Cantini F, Hunder GG, Polymyalgia rheumatica and giant cell arteritis. Lancet. 2008;372(9634): 234-245.
(4) Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. ArthritisRheum. 2013;65(1):1-11.
(5) Ness T, Bley TA, Schmidt WA, Lamprecht P: The diagnosis and treatment of giant cell arteritis. DtschArzteblInt. 2013;110(21):376–86.
(6) Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201-4.
(7) Rieck KL, Kermani TA, Thomsen KM, Harmsen WS, Karban MJ, Warrington KJ. Evaluation for clinical predictors of positive temporal artery biopsy in giant cell arteritis. J Oral MaxillofacSurg. 2011;69(1):36-40.
(8) Mari B, Monteagudo M. Arterial biopsy in giant cell arteries and polymyalgia rheumatica. Eur J InternMed. 2010;21(6):572-3.
(9) Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda Filloy JA, Gonzalez-Juanatey C, Martin J, Llorca J. Epidemiology of giantcell arteritis and polymyalgiarheumatica. ArthritisRheum. 2009;61(10):1454-61.
(10) Mohammad AJ, Nilsson JA, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsyproven giant cell arteritis in southern Sweden. Ann RheumDispublished. 2014.
(11) Vaith P, Warnatz K. Clinical and serological findings of giant-cell arteritis. Z Rheumatol. 2009;68:124–31.
(12) Blockmans D The use of (18F) fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. ClinExpRheumatol. 2009;21:15–22.
(13) Robson JC, Kiran A, Maskell J, Hutchings A, Arden N The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UKAnn Rheum Dis. Published online 2013.
(14) Maksimowicz-McKinnonK,ClarkTM,HoffmanGS:Takayasuarteritis and giant cell arteritis: a spectrum within the same disease? Medicine 2009;88: 221–6.
(15) Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL: Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann RheumDis. 2012.
(16) Nesher G. The diagnosis and classification of giant cell arteritis. J Autoinmmun. 2014.
(17) Figus M, Talarico R, Posarelli C, d‘Ascanio A, Elefante E, Bombardieri S. Ocular involvement in giantcell arteritis. ClinExp Rheumatol. 2013;3(1 Suppl 75):S96.
(18) Charlton R. Optimal management of giant cell arteritis and polymyalgia rheumatica. Therapeutics and Clinical Risk Management. 2012:(8)173–179.
(19) Van Hecke O Polymyalgia rheumatica -- diagnosis and management. AustFam Physician. 2011;40(5):303-6.
(20) Mackie SL, Pease CT Diagnosis and manangement of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips. PostgradMed J. 2013;89(1051):284-92.
(21) Barraclough K, Mallen CD, Helliwell T, Hider SL, Dasgupta B. Di agnosis and management of giant cell arteritis. Br J Gen Pract. 2012;62(599):329-30.
(22) De AraújoMedeiros D, De Miguel E. A ecografiadopplercomcor no diagnóstico da arterite das células gigantes. Acta reumatolport. 2009;34:183-189.
(23) Villa I, Bilbao M, Martinez-Taboada v. Avances en el diagnóstico de las vasculitis de vasos de gran calibre: identificación de biomarca- dores y estudios de imagen. ReumatolClin. 2011;7(S3):S22–S27
(24) Pacheco M, Mínguez M, Martínez A, Bernabeu M. Diagnóstico precoz de las vasculitis de grandes vasos. utilidad de la tomografía por emisión de positrones con la tomografía axial computarizada. ReumatolClin. 2013;9(1):65–68.
(25) Breuer G, Nesher R, Reinus K, Nesher G Association between Histological Features in temporal artery Biopsies and clinical Features of Patients with giant cell arteritis isr Med Assoc J. 2013 Jun;15(6):271-4
(26) Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;287:92-101.
(27) Saedon H, Saedon M, Goodyear S, Papettas T, Marshall C. Temporal artery biopsy for giant cell arteritis: retrospective audit. J R SocMedShRep. 2012;3:73.
(28) Dasgupta B, Borg FA, Hassan N, Alexander L, BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-7
(29) MahrAD,JoverJA,SpieraRF,etal.:Adjunctive methotrexate for treat- ment of giant cell arteritis: an individual patient data meta-analysis. ArthritisRheum. 2007; 56:2789–97.
(30) Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as acorticosteroid-sparing agent in giantcell arteritisand polymyalgiar- heumatica: a case series. Biomed Res int. Epub 2013.
(31) Hoffman GS, Cid MC, RendtZagar KE, Merkel A,Infliximab forma maintenance of glucocorticosteroid induced remission of giant cell arteritis: a randomized trial. Ann internMed. 2007;146(9):621-30.
(32) Karassa FB, Matsagas Mi, Schmidt WA, Ioannidis JPA: Meta- analysis: test performance of ultrasonography for giant-cell arteritis. Ann internMed. 2005;142:359-369.
(33) Villiger PM, Adler S, Kuchen S, et al. Tocilizumabforinduction and maintenance of remission in giantcell arteritis: A phase 2, rando- mised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921.
(34) Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317.
(35) Unizony S, Arias-urdaneta L, Miloslavsky E, et al. Tocilizumabfort- hetreatment of large-vessel vasculitis (giantcell arteritis, Takaya su arteritis) and polymyalgiarheumatica. ArthritisCare Res (Hoboken) 2012;64:1720.
(36) Pfeil A, Oelzner P, Hellmann P. The Treatment of Giant Cell Arteritis in Different Clinical Settings. Front immunol. 2019;9:3129.
Derechos de autor 2019 Revista Paraguaya de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
